India, June 17 -- Lunai Bioworks (LNAI) shares rose more than 50% after the company released a CEO letter outlining major advancements across its biodefense platform and ongoing efforts to address alleged market manipulation.
In the letter, CEO David Weinstein said Lunai has strengthened its position as a next-generation biotechnology company operating at the intersection of artificial intelligence, national security and biology. He highlighted the company's first revenue-generating, multi-year U.S. defense collaboration, which deploys Lunai's AI-enabled platform for chemical threat assessment-marking a shift from research to active commercial engagement with the U.S. government.
Lunai also expanded its national security footprint through...